ESPR
Esperion Therapeutics, Inc.Company with tickers: ESPR
CIK
1434868
CUSIP
29664W105
Shares Outstanding
257,431,942
Investor Relations
https://investor.esperion.com/
13F Activity (30d)
3 filings
2 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Sheldon L. Koenig | Class I director | Appointed | 2026-06-01 |
| J. Martin Carroll | Class I director | Appointed | 2026-06-01 |